Purpose

The purpose of this study was to evaluate the safety and feasibility of transarterial fiducial marker implantation for CyberKnife radiotherapy to treat locally advanced pancreatic cancer.

Materials and methods

Fifteen pancreatic cancer patients were enrolled for transarterial marker implantation. Embolization platinum coils were implanted as a fiducial marker within 20 mm of the cancer edge, and preferably within 3 mm. The technical success of the implantation was defined as implantation of at least one fiducial marker within 20 mm of the target tumor. Irradiation was performed using the CyberKnife system.

Results

For 14 of 15 patients, transarterial implantation was successfully performed, and for 13 of 14 patients, the tracking marker was implanted within 3 mm of the cancer. Tracking instability was observed in two patients, but irradiation was accomplished in all 14 patients. No major complications caused by the implantation procedure were observed. The median overall survival after irradiation was 13.8 months, and the 1- and 2-years survival rates were 62.9% and 32.3%, respectively.

Conclusion

Transarterial fiducial marker implantation for pancreatic cancer can be safely performed for tracking, and it will be a valuable alternative approach to percutaneous fiducial marker implantation.

中文翻译：

---

射波刀放射治疗胰腺癌经动脉基准标记植入14例体会.

目的

本研究的目的是评估射波刀放射治疗局部晚期胰腺癌经动脉基准标记植入的安全性和可行性。

材料和方法

15 名胰腺癌患者参加了经动脉标记物植入。栓塞铂金线圈作为基准标记植入癌边缘 20 毫米内，最好在 3 毫米内。植入的技术成功定义为在目标肿瘤 20 毫米内植入至少一个基准标记。使用 Cyber​​Knife 系统进行辐照。

结果

对于 15 名患者中的 14 名，成功进行了经动脉植入，对于 14 名患者中的 13 名，跟踪标记被植入了距离癌症 3 毫米的范围内。在两名患者中观察到跟踪不稳定性，但在所有 14 名患者中均完成了照射。没有观察到植入过程引起的严重并发症。放疗后的中位总生存期为 13.8 个月，1 年和 2 年生存率分别为 62.9% 和 32.3%。

结论

胰腺癌的经动脉基准标记植入可以安全地进行跟踪，这将是经皮基准标记植入的一种有价值的替代方法。